BACKGROUND: Rivaroxaban PK is highly sensitive to hemodynamic variations due to dual renal and hepatic elimination. While heart failure (HF) alters drug disposition, the impact of quantitative ventricular metrics like left ventricular ejection fraction (LVEF) on PK rivaroxaban remains poorly characterized. This study aims to develop and externally validate a population PK/PD model of rivaroxaban […]
Author: W Tang
Pharmacometrics Insights into Major Bleeding Risk in Rivaroxaban-treated Atrial Fibrillation Patients
Introduction: Pharmacometrics time-to-event (TTE) modelling complements therapeutic drug monitoring (TDM) in assessing drug efficacy and safety. In atrial fibrillation (AF) patients on rivaroxaban, heart failure (HF) is an independent predictor of bleeding. Given rivaroxaban’s high protein binding and hepatic metabolism, organ congestion in HF may influence drug disposition and anticoagulation outcomes. Objectives: This study aimed […]